HRT Financial LP Makes New $3.11 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

HRT Financial LP purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 69,796 shares of the biopharmaceutical company’s stock, valued at approximately $3,110,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its position in Celldex Therapeutics by 109.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,024 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 534 shares during the period. Point72 Hong Kong Ltd lifted its stake in Celldex Therapeutics by 57.9% in the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 511 shares in the last quarter. Strs Ohio purchased a new position in Celldex Therapeutics in the 4th quarter valued at about $53,000. Great West Life Assurance Co. Can purchased a new position in Celldex Therapeutics in the 3rd quarter valued at about $58,000. Finally, Atlas Capital Advisors LLC purchased a new position in Celldex Therapeutics in the 3rd quarter valued at about $76,000.

Analyst Ratings Changes

CLDX has been the topic of a number of research reports. StockNews.com initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, May 18th. They issued a “sell” rating on the stock. Cantor Fitzgerald decreased their price target on shares of Celldex Therapeutics from $55.00 to $54.00 in a research note on Friday, May 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $73.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, March 1st.

Celldex Therapeutics Price Performance

CLDX opened at $30.37 on Friday. The company’s 50 day simple moving average is $33.83 and its two-hundred day simple moving average is $39.07. Celldex Therapeutics, Inc. has a 1-year low of $19.85 and a 1-year high of $48.40. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -12.05 and a beta of 2.10.

Celldex Therapeutics (NASDAQ:CLDX – Get Rating) last released its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.03. Celldex Therapeutics had a negative net margin of 3,766.22% and a negative return on equity of 32.84%. The business had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.16 million. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

(Get Rating)

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.